BioNTech Trial Termination and Market Impact
On Friday, 28 August 2026, BioNTech SE (NASDAQ:BNTX) reported that its shares declined approximately 10% following the announcement that it would terminate a Phase 2 clinical trial identified as BNT122‑01. The trial was evaluating an investigational individualized mRNA cancer immunotherapy, autogene cevumeran, as an adjuvant monotherapy for patients with ctDNA‑positive, surgically resected Stage II or Stage III colorectal cancer. Development of this therapy is being conducted jointly with Genentech, a member of the Roche Group.
The termination decision was based on a recommendation from an independent Data Safety Monitoring Board (DSMB). The DSMB identified a numerical imbalance in overall survival between the treatment and control arms and concluded that further continuation was unlikely to alter the efficacy outcome. It noted that the futility boundary for the study had been crossed in October 2025, prompting the recommendation to discontinue treatment and end the trial.
The company emphasized that the DSMB did not identify any new safety signals associated with autogene cevumeran. The trial had been designed to determine whether the mRNA immunotherapy as a monotherapy could prevent disease recurrence in high‑risk patients compared with a watchful‑waiting approach.
BioNTech stated that it will conduct a thorough analysis of the trial data to gain insights into patient‑population selection and to inform its clinical development strategy for potential future investigational mRNA cancer immunotherapies. The results of this analysis will be shared with the scientific and medical community at an appropriate time.
The announcement also clarified that BioNTech’s other Phase 2 study, IMcode003, which evaluates autogene cevumeran in combination with checkpoint inhibition and chemotherapy as an adjuvant treatment for pancreatic ductal adenocarcinoma, remains unaffected and will continue as planned.